According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

You raise both non-dilutive funding through NIH which is the very best, obviously, and then as well as dilutive and to try to move the program forward. PE:How risky is the traditional pain medication ...

Each year, millions of people in America are prescribed a medicine for acute pain.Now, for the first time in over 20 years, ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

The Food and Drug Administration (FDA) recently approved a new, non-opioid (non-narcotic) prescription pill, suzetrigine (SUE ...

Jason, a 42-year-old father of two, has been battling back pain for weeks. Scrolling through his phone, he sees ad after ad ...

To read more letters to the editor, go to oregonlive.com/opinion.

Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...

A research team funded by the National Institutes of Health (NIH) has developed a medication that shows promise in ... and are an important step towards developing novel, non-addictive treatments for ...

“We appreciate the support of our new and existing investors as we work to bring best-in-class, non-addictive ... for chronic pain. Latigo develops non-opioid pain medications that directly ...

More than one in three adults in the UK suffers from chronic pain — just under 28 million people, according to the National ...